Haleon PLC Sponsored ADR $HLN Shares Sold by Douglas Lane & Associates LLC

Posted by George Bondi on Oct 9th, 2026

Douglas Lane & Associates LLC decreased its position in Haleon PLC Sponsored ADR (NYSE:HLN – Free Report) by 2.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,546,637 shares of the company’s stock after selling 145,753 shares during the quarter. Douglas Lane & Associates LLC owned 0.15% of Haleon worth $58,920,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in HLN. Western Wealth Management LLC purchased a new position in Haleon in the 1st quarter valued at approximately $29,000. Annis Gardner Whiting Capital Advisors LLC raised its stake in shares of Haleon by 402.0% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock valued at $30,000 after acquiring an additional 2,404 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Haleon by 20.4% in the second quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock valued at $58,000 after acquiring an additional 1,055 shares in the last quarter. Gryphon Financial Partners LLC purchased a new position in Haleon in the first quarter valued at $101,000. Finally, NWF Advisory Services Inc. purchased a new position in Haleon in the first quarter valued at $102,000. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research note on Friday, September 25th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Haleon in a research note on Wednesday, September 9th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Haleon in a research note on Tuesday, August 11th. Jefferies Financial Group reiterated a “buy” rating on shares of Haleon in a report on Wednesday, September 23rd. Finally, Rothschild & Co Redburn downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Read Our Latest Stock Analysis on Haleon

Haleon Stock Performance

Haleon stock traded up $0.04 during mid-day trading on Friday, reaching $9.29. 7,238,202 shares of the company were exchanged, compared to its average volume of 10,443,843. The firm’s 50-day simple moving average is $9.56 and its two-hundred day simple moving average is $9.51. Haleon PLC Sponsored ADR has a twelve month low of $8.65 and a twelve month high of $11.28. The firm has a market cap of $40.88 billion, a PE ratio of 23.83, a price-to-earnings-growth ratio of 2.03 and a beta of 0.14. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.52 and a current ratio of 0.69.

Haleon Cuts Dividend

The business also recently declared a dividend, which was paid on Thursday, September 17th. Stockholders of record on Friday, August 14th were issued a $0.0642 dividend. The ex-dividend date was Friday, August 14th. This represents a dividend yield of 132.0%. This is a drop from Haleon’s previous dividend of $0.1307. Haleon’s payout ratio is 30.77%.

About Haleon

(Free Report)

Haleon plc (NYSE: HLN) is a global consumer healthcare company headquartered in Weybridge, England. The company develops, manufactures and markets over-the-counter medicines, oral healthcare products, nutritional supplements and other consumer health products sold through pharmacies, retailers and e-commerce channels.

Its portfolio includes well-known brands such as Sensodyne, Polident and parodontax in oral healthcare; Advil, Panadol, Voltaren and Theraflu in pain relief and respiratory care; and Centrum and Emergen-C in vitamins, minerals and supplements.